DIVIGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIVIGEL (DIVIGEL).
Estradiol replacement therapy; binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to proliferation of endometrial and breast epithelium, and modulation of gonadotropin secretion.
| Metabolism | Primarily hepatic metabolism via CYP3A4; also undergoes conjugation (glucuronidation) and sulfation; enterohepatic recirculation. |
| Excretion | Urine (approximately 90-95% as glucuronide and sulfate conjugates, with less than 5% as unchanged drug); feces (approximately 5-10% via biliary excretion) |
| Half-life | Terminal elimination half-life of estradiol is 13-15 hours; clinical context: due to enterohepatic recirculation, serum levels may fluctuate; transdermal delivery avoids first-pass hepatic metabolism, resulting in more stable levels |
| Protein binding | 98-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin |
| Volume of Distribution | Vd approximately 1-2 L/kg, indicating extensive distribution into tissues; clinical meaning: reflects wide distribution to target organs such as breast, uterus, and adipose tissue |
| Bioavailability | Transdermal gel: approximately 10-20% of the applied dose (due to incomplete absorption and retention in the skin depot); avoids first-pass hepatic metabolism, thus effective at lower doses compared to oral |
| Onset of Action | Transdermal gel: detectable serum estradiol levels within 15-30 minutes; clinical effects (e.g., vasomotor symptom relief) may be observed within 1-2 weeks |
| Duration of Action | After single application, serum estradiol returns to baseline within 24-48 hours; clinical effects for hormone replacement require continuous daily application; steady-state achieved by day 3-5 |
| Molecular Weight | 272.38 |
Transdermal gel: 0.25-1.0 g applied once daily to upper thigh, abdomen, or upper arm. Each gram contains 1 mg estradiol.
| Dosage form | GEL |
| Renal impairment | No specific dose adjustment recommended based on GFR; estradiol is not significantly renally cleared. |
| Liver impairment | Contraindicated in severe hepatic dysfunction (Child-Pugh class C). In mild to moderate (Child-Pugh A/B), use with caution and monitor. |
| Pediatric use | Not FDA-approved for use in children; efficacy and safety not established. |
| Geriatric use | Use lowest effective dose; consider increased risk of thromboembolic events, cardiovascular disease, and dementia in women >65 years. |
| 1st trimester | Contraindicated. Estrogens are associated with an increased risk of congenital anomalies, including cardiovascular and urogenital defects, and may cause fetal harm. |
| 2nd trimester | Contraindicated. Use is not recommended due to potential adverse effects on fetal development. |
| 3rd trimester | Contraindicated. Estrogen exposure in utero may be associated with an increased risk of reproductive tract abnormalities and other adverse outcomes. |
Clinical note
Comprehensive clinical and safety monograph for DIVIGEL (DIVIGEL).
| Placental transfer | Estrogens cross the placenta. The degree of transfer is significant, with fetal concentrations reaching therapeutic levels. |
| Breastfeeding | Estrogens are excreted in human breast milk and may reduce milk production and quality. Use during breastfeeding is not recommended. If used, monitor the infant for potential estrogenic effects. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risk of venous thromboembolism, stroke, and possibly dementia. Estrogen plus progestin has been associated with increased risk of breast cancer, stroke, VTE, and dementia.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancer (except in appropriately selected patients)Known or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolismActive or history of arterial thromboembolismKnown protein C, protein S, or antithrombin deficiency or other thrombophilic disordersHypersensitivity to any ingredient in DIVIGEL
| Precautions | Cardiovascular disorders (e.g., coronary heart disease, stroke, VTE), malignant neoplasms (endometrial cancer, breast cancer), gallbladder disease, hypercalcemia, fluid retention, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, hepatic hemangiomas, exacerbation of endometriosis, severe hypocalcemia in hypoparathyroidism, and thyroid hormone effects. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 |
| Teratogenic Risk | Divigel (estradiol) is contraindicated in pregnancy. Estrogens are associated with an increased risk of congenital anomalies, including cardiovascular and urogenital defects, when used during the first trimester. In the second and third trimesters, exposure may cause feminization of male fetuses, functional genital tract abnormalities, and potential long-term reproductive effects. Use is not recommended at any stage. |
| Fetal Monitoring | If inadvertent exposure during pregnancy occurs, monitor fetal development with ultrasound for structural anomalies. No specific monitoring is required for Divigel therapy as it is contraindicated in pregnancy. |
| Fertility Effects | Exogenous estrogens may suppress ovulation and impair fertility during use. Reversible upon discontinuation. Long-term effects on fertility are not well documented. |
| No significant food interactions. Grapefruit juice may increase estradiol exposure; avoid excessive intake. |
| Clinical Pearls | Divigel (estradiol gel) is a transdermal estrogen therapy for moderate-to-severe vasomotor symptoms of menopause. Apply to clean, dry, non-irritated skin on upper thigh or calf, rotating sites daily. Do not apply to breasts or genital area. Avoid sun exposure or heating pads over application site. Monitor for endometrial hyperplasia; add progestin if uterus intact. |
| Patient Advice | Apply gel at the same time each day to clean, dry skin on upper thigh or calf. Rotate application sites daily. · Do not apply to breasts, face, or genital area. Avoid contact with others until gel dries (about 5 minutes). · Wash hands thoroughly after application. Avoid water, sunscreen, or lotion on the application site for 2-3 hours. · Report unusual vaginal bleeding, breast lumps, leg pain, or jaundice immediately. · Do not smoke or use nicotine products while on estrogen therapy. |